Seeking Alpha

OncoMed Pharmaceuticals initiates breast cancer study with vantictumab

  • OncoMed Pharmaceuticals (OMED) starts a Phase 1b dose escalation trial for vantictumab (with paclitaxel) in patients with first-, second- and third-line, locally advanced or metastatic HER2 negative breast cancer.
  • OMED intends to initiate three Phase 1 trials of vantictumab this year. (PR)
  • The company is developing the drug with Bayer (BAYZF).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|